John Flavin, Portal Innovations CEO, joins 'Fast Money' to talk what we can expect to see from the J.P. Morgan Healthcare conference this year.

Scrawlspace spotlighted a group of artists visually reimagining and exploring language, texts and writings epitomizing the Black experience.

Obesity is a complex health issue that affects millions of people worldwide. Unfortunately, it is often accompanied by stigma and discrimination, which can have a significant negative impact on ...

Big money, big ideas and big egos — the art world has all the necessary ingredients ... Rie Kudan revealed that around 5% of the work was generated, word-for-word, by AI.

A Microsoft 365 subscription includes Microsoft Word for writing, PowerPoint for creating presentations, Outlook for email and OneDrive for cloud storage -- and typically, it doesn't come cheap.

In the beginning was the Word, and the Word was with God, and the Word was God. He was in the beginning with God. All things were made through him, and without him was not any thing made that was made ...

In a first, scientists at the World Health Organisation (WHO) have endorsed a new class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar ...

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

The numbers showed that both average body mass index (BMI) and obesity rates across the population fell in 2023, having risen steadily since 2013 before leveling in 2022. While we don't yet have any ...

A new type of obesity drug being developed by Novo Nordisk has fallen short of expectations set by the company in a closely watched Phase 3 trial, causing shares to lose nearly a fifth of their value ...

(AP Photo/Patrick Sison, File) WASHINGTON (AP) — Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase ...